Advertisement
Welcome to our EJNMMI Journal Family page, which highlights some of our featured content and the latest developments from the EJNMMI group of journals.
Stay up to date with article collections, editor’s highlights, upcoming events, and read our latest research!
We would like to announce the following changes in the editorship of the EJNMMI Journal Family, effective from the 1st January 2019.
Prof. Ignasi Carrió, Hospital Sant Pau, Spain, decided to retire from his position as the Editor-in-Chief of the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) after 15 years of service.
We would like to thank Prof. Carrió for all his dedication and commitment to EJNMMI and express our sincere gratitude. During his time as Editor-in-Chief, EJNMMI has become the world-leading journal in nuclear medicine and following his vision, four new journals were launched under the umbrella of EJNMMI, giving rise to the EJNMMI Journal Family. Prof. Carrió will therefore always be known as the founding father of the EJNMMI Journal Family.
We are pleased to announce that Prof. Arturo Chiti, Humanitas University, Italy, is the new Editor-in-Chief of EJNMMI, effective 1st January 2019. We are also pleased to announce that succeeding him as Editor-in-Chief of the European Journal of Hybrid Imaging is Prof. Francesco Giammarile, University Hospital Lyon, France.
Prof. Chiti is the Full Professor in Diagnostic Imaging and Radiotherapy at the Humanitas University in Milan and the Director of the Nuclear Medicine Department at the Humanitas Research Hospital. From 2015-2016 he was the President of the European Association of Nuclear Medicine (EANM). Prof. Chiti became the first Editor-in-Chief of the European Journal of Hybrid Imaging in 2016, and we thank him for his immense engagement in ensuring an outstanding start for the newest journal of the EJNMMI Journal Family. We are glad to welcome him as the Editor-in-Chief of EJNMMI.
Prof. Giammarile is a Professor in the academic Nuclear Medicine Department of University Hospital Lyon and a Senior Technical Officer at the International Atomic Energy Agency. He is also the EANM Congress Chair for 2017-2019.
The EJNMMI represents the highest level of knowledge dissemination in the fields of nuclear medicine and molecular imaging. In the past years, its impact on the scientific community has raised to a level that was never reached before. I will do my best to continue this trend, with the support of all our authors, reviewers and editorial board members.
Arturo Chiti
Humanitas University, Italy
The EJHI is a recent Open Access journal, a member of the EJNMMI, dedicated to the use of hybrid and multimodality imaging in clinical practice, clinical trials and pre-clinical research. With recent technological advances, this is a particularly exciting time for our field. For my part, I'm ready to do my best, with the support of all our authors, reviewers and editorial board members, for the continued success of our journal in the years to come.
Francesco Giammarile
University Hospital Lyon, France
Highly ranked among journals in its field, the European Journal of Nuclear Medicine and Molecular Imaging provides a forum for the exchange of clinical and scientific information for the nuclear medicine community and allied professions involved in the functional, metabolic and molecular investigation of disease. Find out more about the journal or read our latest content.
Annual Journal Metrics
7.704 2-year Impact Factor, the highest Impact Factor of ANY nuclear medicine journal worldwide.
2.458 SCImago Journal Rank.
Wide readership and dissemination, with 698,022 articles downloaded last year.
Rapid manuscript handling with only 19 days from submission to first decision.
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease. Learn more.
Annual Journal Metrics
Rapid peer review process with only 33 days from submission to first decision, 77 days from submission to acceptance, and 17 days from acceptance to publication.
2.630 2-year Impact Factor, ranked 44th in Radiology, Nuclear Medicine and Medical Imaging in Web of Science, putting it in the second quartile of journals.
Wide readership and dissemination, with 188,554 articles downloaded last year.
1.003 SCImago Journal Rank puts the journal in the first quartile for SJR.
EJNMMI Physics is an international platform for scientists, users and adopters of nuclear medicine with a particular interest in physics matters. As a companion journal to the European Journal of Nuclear Medicine and Molecular Imaging, this journal has a multi-disciplinary approach with a focus on applied physics and mathematics as well as imaging systems engineering and prototyping in nuclear medicine. Learn more.
Annual Journal Metrics
Rapid peer review process with only 65 days from submission to first decision, 156 days from submission to acceptance, and 62 days from acceptance to publication.
0.825 SCImago Journal Rank puts the journal in the second quartile for SJR.
Wide readership and dissemination, with 74,739 articles downloaded last year.
1.98 CiteScore, putting the journal 77th and in the second quartile for Radiology, Nuclear Medicine and Imaging.
EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The open access journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. Learn more.
Annual Journal Metrics
Rapid peer review process with only 41 days from submission to first decision, 75 days from submission to acceptance, and 28 days from acceptance to publication.
Wide readership and dissemination, with 37,061 articles downloaded last year.
The European Journal of Hybrid Imaging publishes new basic and clinical research in the field of imaging, conducted with hybrid or multimodality techniques. The unique characteristic of this journal is the focus on hybrid and multimodality imaging technology in different clinical and research fields: oncology, neurology, cardiology, orthopedics, infection imaging. Learn more.
Annual Journal Metrics
Rapid peer review process with only 32 days from submission to first decision, 90 days from submission to acceptance, and 62 days from acceptance to publication.
Growing readership and dissemination, with 19,771 articles downloaded last year.
Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT (Schwenck et al., 2017)
doi: 10.1007/s00259-016-3490-6
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients (Giesel et al., 2017)
doi: 10.1007/s00259-016-3573-4
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour (Uprimmy et al., 2017)
doi: 10.1007/s00259-017-3631-6
Most Cited Paper 2018
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience (Afshar-Oromieh et al., 2014)
doi: 10.1007/s00259-013-2660-z
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617 — preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 (Umbricht et al., 2017)
doi: 10.1186/s13550-017-0257-4C
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey (Sjögreen Gleisner et al., 2017)
doi: 10.1186/s40658-017-0193-4
47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes (Domanich et al., 2017)
doi: 10.1186/s41181-017-0024-x
Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer (Kuji et al., 2017)
doi: 10.1186/s41824-017-0006-y
Imaging and dosimetry for radionuclide-based therapy
EJNMMI Physics welcomes submissions on imaging and dosimetry for radionuclide-based therapy. Radionuclide therapy and molecular radiotherapy are established modalities for treatment of certain cancer types. For this collection, we invite contributions on different aspects of imaging and dosimetry of radionuclides for therapeutic use. Find out more.
The EANM Board decided to allocate funds to a dedicated Publication Fee Sponsorship Programme for the selected journals in the EJNMMI journal family. Through this programme, the EANM will cover the charges that arise for publications in the open access journals EJNMMI Physics, EJNMMI Radiopharmacy and Chemistry and the European Journal of Hybrid Imaging. Find out more here.
